* ABL and SANOFI to collaborate on the development of ABL301, a potential first-in-class bispecif...
* South Korea's MFDS clears IND application for a Phase 1 study evaluating the safety and prelimi...
* ABL503/TJ-L14B demonstrates stronger anti-tumor efficacy than anti-PD-L1 or anti-4-1BB monother...